Display options
Cite
Van den Bogerd B, Zakaria N, Matthyssen S, et al. Exploring the Mesenchymal Stem Cell Secretome for Corneal Endothelial Proliferation. Stem Cells Int. 2020;2020:5891393doi: 10.1155/2020/5891393.
Van den Bogerd, B., Zakaria, N., Matthyssen, S., Koppen, C., & Ní Dhubhghaill, S. (2020). Exploring the Mesenchymal Stem Cell Secretome for Corneal Endothelial Proliferation. Stem cells international, 20205891393. https://doi.org/10.1155/2020/5891393
Van den Bogerd, Bert, et al. "Exploring the Mesenchymal Stem Cell Secretome for Corneal Endothelial Proliferation." Stem cells international vol. 2020 (2020): 5891393. doi: https://doi.org/10.1155/2020/5891393
Van den Bogerd B, Zakaria N, Matthyssen S, Koppen C, Ní Dhubhghaill S. Exploring the Mesenchymal Stem Cell Secretome for Corneal Endothelial Proliferation. Stem Cells Int. 2020 Feb 05;2020:5891393. doi: 10.1155/2020/5891393. eCollection 2020. PMID: 32089707; PMCID: PMC7025074.
Copy Download .nbib Format: NLM
Share it on

Stem Cells Int. 2020 Feb 05;2020:5891393. doi: 10.1155/2020/5891393. eCollection 2020.

Exploring the Mesenchymal Stem Cell Secretome for Corneal Endothelial Proliferation.

Stem cells international

Bert Van den Bogerd, Nadia Zakaria, Steffi Matthyssen, Carina Koppen, Sorcha Ní Dhubhghaill

Affiliations

  1. Antwerp Research Group for Ocular Science (ARGOS), Translational Neurosciences, Faculty of Medicine, University of Antwerp, Wilrijk, Belgium.
  2. Department of Ophthalmology, Antwerp University Hospital, Edegem, Belgium.
  3. Netherlands Institute for Innovative Ocular Surgery (NIIOS), Rotterdam, Netherlands.

PMID: 32089707 PMCID: PMC7025074 DOI: 10.1155/2020/5891393

Abstract

Ex vivo grown human corneal endothelial cells (HCEnC) are a new emerging treatment option to treat visually impaired patients aimed at alleviating the current global donor shortage. Expanding HCEnC is still challenging, and obtaining cells in sufficient quantities is a limiting factor. It is already known that conditioned medium obtained from bone marrow mesenchymal stem cells can stimulate the proliferation of endothelial cells. The aim of this study was to take this work a step further to identify some of the underlying factors responsible. We confirmed the stimulatory effect of the mesenchymal stem cell secretome seen previously and separated the exosomes from the soluble proteins using size exclusion chromatography. We demonstrated the presence of exosomes and soluble proteins in the early and late fractions, respectively, with transmission electron microscopy and protein assays. Proliferation studies demonstrated that growth stimulation could be reproduced with the later protein-rich fractions but not with the exosome-rich fraction. Antibody assays revealed the presence of the secreted proteins EGF, IGFBP2, and IGFBP6 in protein-high fractions, but the growth enhancement was not seen with purified protein formulations. In conclusion, we confirmed the stimulatory effect of stem cell-conditioned medium and have determined that the effect was attributable to the proteins rather than to the exosomes. We were not able to reproduce the growth stimulation, however, with the pure recombinant protein candidates tested. Specific identification of the underlying proteins using proteomics could render a bioactive protein that can be used for

Copyright © 2020 Bert Van den Bogerd et al.

Conflict of interest statement

Nadia Zakaria is an employee of Novartis.

References

  1. Nat Rev Drug Discov. 2013 May;12(5):347-57 - PubMed
  2. Stem Cells Int. 2018 Apr 29;2018:8146834 - PubMed
  3. Mol Vis. 2010 Apr 08;16:611-22 - PubMed
  4. PLoS One. 2013 Jul 23;8(7):e69009 - PubMed
  5. Stem Cell Res Ther. 2017 Dec 20;8(1):287 - PubMed
  6. J Tissue Eng Regen Med. 2018 Apr;12(4):e2020-e2028 - PubMed
  7. N Engl J Med. 2018 Sep 20;379(12):1184-5 - PubMed
  8. J Extracell Vesicles. 2014 Dec 22;3:26913 - PubMed
  9. Endocr Rev. 2002 Dec;23(6):824-54 - PubMed
  10. Invest Ophthalmol Vis Sci. 1997 Mar;38(3):779-82 - PubMed
  11. Annu Rev Vis Sci. 2017 Sep 15;3:69-90 - PubMed
  12. Exp Eye Res. 2013 Nov;116:36-46 - PubMed
  13. Stem Cells. 2006 Feb;24(2):386-98 - PubMed
  14. Exp Eye Res. 1979 Feb;28(2):147-57 - PubMed
  15. PLoS One. 2013;8(2):e58000 - PubMed
  16. Am J Pathol. 2012 Jul;181(1):268-77 - PubMed
  17. Mol Ther Methods Clin Dev. 2015 Apr 29;2:15014 - PubMed
  18. J Extracell Vesicles. 2018 Jul 03;7(1):1490143 - PubMed
  19. NPJ Regen Med. 2019 Apr 16;4:8 - PubMed
  20. Invest Ophthalmol Vis Sci. 2016 Mar;57(3):1284-92 - PubMed
  21. J Cell Sci. 2012 Aug 1;125(Pt 15):3636-48 - PubMed
  22. J Transl Med. 2011 Apr 25;9:47 - PubMed
  23. J Proteome Res. 2012 Dec 7;11(12):5611-29 - PubMed
  24. Surv Ophthalmol. 2018 Mar - Apr;63(2):149-165 - PubMed
  25. N Engl J Med. 2018 Mar 15;378(11):995-1003 - PubMed
  26. Stem Cells Dev. 2016 Jul 15;25(14):1073-83 - PubMed
  27. Biomed Res Int. 2014;2014:965849 - PubMed
  28. PLoS One. 2013;8(3):e59020 - PubMed
  29. Int J Mol Sci. 2017 Aug 25;18(9): - PubMed

Publication Types